KR101828433B1 - 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물 - Google Patents

혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물 Download PDF

Info

Publication number
KR101828433B1
KR101828433B1 KR1020167030334A KR20167030334A KR101828433B1 KR 101828433 B1 KR101828433 B1 KR 101828433B1 KR 1020167030334 A KR1020167030334 A KR 1020167030334A KR 20167030334 A KR20167030334 A KR 20167030334A KR 101828433 B1 KR101828433 B1 KR 101828433B1
Authority
KR
South Korea
Prior art keywords
composition
alpha
iαip
protein
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167030334A
Other languages
English (en)
Korean (ko)
Other versions
KR20160129914A (ko
Inventor
요우-핀 림
에드워드 에스. 설야
피터 브르네
Original Assignee
프로테라 바이오로직스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로테라 바이오로직스, 인크. filed Critical 프로테라 바이오로직스, 인크.
Publication of KR20160129914A publication Critical patent/KR20160129914A/ko
Application granted granted Critical
Publication of KR101828433B1 publication Critical patent/KR101828433B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020167030334A 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물 Active KR101828433B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13026908P 2008-05-28 2008-05-28
US61/130,269 2008-05-28
PCT/US2009/003291 WO2009154695A1 (en) 2008-05-28 2009-05-28 Preparation and composition of inter-alpha inhibitor proteins from blood

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107029406A Division KR101714008B1 (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177027338A Division KR20170116196A (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물

Publications (2)

Publication Number Publication Date
KR20160129914A KR20160129914A (ko) 2016-11-09
KR101828433B1 true KR101828433B1 (ko) 2018-03-29

Family

ID=41434346

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167030334A Active KR101828433B1 (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물
KR1020107029406A Active KR101714008B1 (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물
KR1020177027338A Ceased KR20170116196A (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020107029406A Active KR101714008B1 (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물
KR1020177027338A Ceased KR20170116196A (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물

Country Status (13)

Country Link
US (3) US9139641B2 (enExample)
EP (1) EP2291654B1 (enExample)
JP (3) JP5793076B2 (enExample)
KR (3) KR101828433B1 (enExample)
CN (2) CN102112876B (enExample)
AU (1) AU2009260822B2 (enExample)
BR (2) BR122020017577B1 (enExample)
CA (1) CA2726281C (enExample)
DK (1) DK2291654T3 (enExample)
ES (1) ES2673005T3 (enExample)
PT (1) PT2291654T (enExample)
TR (1) TR201808152T4 (enExample)
WO (1) WO2009154695A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289252C1 (en) 2003-11-08 2013-06-20 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use
AU2009260822B2 (en) 2008-05-28 2016-09-22 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from blood
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma
KR101443257B1 (ko) * 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
EP3041857B1 (en) * 2013-09-04 2019-05-08 EMD Millipore Corporation Protein a chromatography
HUE057005T2 (hu) * 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
CN104138374A (zh) * 2014-07-26 2014-11-12 滨州医学院 硫酸阿扎那韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用
WO2017066683A1 (en) * 2015-10-15 2017-04-20 Plasma Technologies, Llc Methods for extracting proteins from blood plasma
EP3512539A4 (en) 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
BR112019022358A2 (pt) * 2017-04-25 2020-05-19 Prothera Biologics Inc métodos para quantificar proteínas inibidoras inter-alfa
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
US11634680B2 (en) * 2017-11-20 2023-04-25 Lonza Ltd Process and system for propagating cell cultures while preventing lactate accumulation
EP3870147A4 (en) * 2018-10-24 2022-08-31 Prothera Biologics, Inc. INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF
CN109900689B (zh) * 2019-03-28 2021-12-10 复星诊断科技(长沙)有限公司 抗干扰膜及肝功能联合测试条
AU2021377336A1 (en) 2020-11-16 2023-07-06 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
WO2023089503A1 (en) * 2021-11-16 2023-05-25 Takeda Pharmaceutical Company Limited Inter-alpha inhibitor protein formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839298A (en) * 1986-02-14 1989-06-13 Akzo N.V. Virus inactivating diluents used in immunoassays
ATE100210T1 (de) 1988-11-01 1994-01-15 Sanol Arznei Schwarz Gmbh Lyophilisiertes mdm enthaltende zusammensetzung und verfahren zu deren herstellung.
GB8928501D0 (en) 1989-12-18 1990-02-21 Unilever Plc Reagents
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
JPH0953775A (ja) 1995-06-09 1997-02-25 Kubota Corp 埋設管路
US6313091B1 (en) * 1995-07-20 2001-11-06 New York University Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method
AU5134799A (en) 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6489128B1 (en) 2000-01-24 2002-12-03 Rhode Island Hospital, A Lifespan Partner Methods for detecting cancer of the central nervous system
US6660482B1 (en) 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
WO2002030983A2 (de) 2000-10-13 2002-04-18 Octapharma Ag Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2426102A1 (en) 2000-12-08 2002-08-01 Genentech, Inc. Method of diagnosing and treating cartilaginous disorders
GB0114709D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Stabilised formulations of amlodipine maleate
US20030027848A1 (en) 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
US20040009212A1 (en) * 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
KR20040098023A (ko) * 2002-03-26 2004-11-18 테바 파마슈티컬 인더스트리즈 리미티드 약물 미세입자
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
JP2007506681A (ja) 2003-09-23 2007-03-22 ピーディーエル バイオファーマ，インコーポレイティド 抗ｉｌ−２受容体抗体による呼吸器疾患の治療
AU2004289252C1 (en) * 2003-11-08 2013-06-20 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use
PL1765866T3 (pl) 2004-06-07 2014-06-30 Therapure Biopharma Inc Wydzielanie białek osocza lub surowicy
US7939282B2 (en) 2004-10-21 2011-05-10 Rhode Island Hospital Methods for detecting sepsis
CN101160133B (zh) 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CA2623940C (en) 2005-09-27 2017-01-10 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2008067655A1 (en) 2006-12-05 2008-06-12 Q6 Biomaterials Inc. Biocompatible hydrogel-based scaffolds
AU2009260822B2 (en) 2008-05-28 2016-09-22 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from blood
EP2313106B1 (en) 2008-07-18 2016-03-30 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
AU2009325088B2 (en) 2008-12-10 2014-06-19 Duke University Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US9562906B2 (en) 2010-06-10 2017-02-07 National University Of Singapore Methods for detection of gastric cancer
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Chromatography A, Vol 1065, Pages 39-43 (2005)*

Also Published As

Publication number Publication date
CA2726281A1 (en) 2009-12-23
US20110190194A1 (en) 2011-08-04
US20170157224A1 (en) 2017-06-08
PT2291654T (pt) 2018-06-15
US20160145318A1 (en) 2016-05-26
EP2291654A1 (en) 2011-03-09
JP2015155434A (ja) 2015-08-27
US10076559B2 (en) 2018-09-18
AU2009260822A1 (en) 2009-12-23
KR101714008B1 (ko) 2017-03-09
KR20160129914A (ko) 2016-11-09
DK2291654T3 (en) 2018-06-14
BR122020017577B1 (pt) 2021-10-26
KR20170116196A (ko) 2017-10-18
BRPI0913949A2 (pt) 2015-10-20
JP5793076B2 (ja) 2015-10-14
JP2018008941A (ja) 2018-01-18
CN102112876B (zh) 2017-12-08
EP2291654B1 (en) 2018-04-11
EP2291654A4 (en) 2011-08-24
US9139641B2 (en) 2015-09-22
KR20110053404A (ko) 2011-05-23
TR201808152T4 (tr) 2018-07-23
CN106928346B (zh) 2021-09-07
AU2009260822B2 (en) 2016-09-22
JP6309915B2 (ja) 2018-04-11
CA2726281C (en) 2023-04-18
CN106928346A (zh) 2017-07-07
ES2673005T3 (es) 2018-06-19
WO2009154695A1 (en) 2009-12-23
CN102112876A (zh) 2011-06-29
JP2011524343A (ja) 2011-09-01
US9758570B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
KR101828433B1 (ko) 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물
JP5010920B2 (ja) 治療に使用するためのヒト血漿由来のインターα阻害タンパク質の調製方法及びその組成物
CN101160133B (zh) 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
HK1243715A1 (en) Preparation and composition of inter-alpha inhibitor proteins from blood
HK1243715B (zh) 来自血液的间-α抑制物蛋白的制备和组合物
CN103142650B (zh) 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
HK1230523A1 (en) Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
HK1121670B (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161028

Application number text: 1020107029406

Filing date: 20101228

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161125

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161220

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161220

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170926

Application number text: 1020107029406

Filing date: 20101228

PJ0201 Trial against decision of rejection

Patent event date: 20170926

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170627

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20171115

Appeal identifier: 2017101004622

Request date: 20170926

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20170926

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20170926

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170220

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20161125

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20171115

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20171031

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180206

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180207

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210202

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220125

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240123

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250122

Start annual number: 8

End annual number: 8